Gastroesophageal Cancer – Current Treatment – Current Treatment: Physician Insights – Gastroesophageal Cancer (US)
The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the HER2-negative setting is on the brink of a significant transformation. Immune checkpoint inhibitors such as Opdivo and Keytruda have achieved unparalleled penetration into all populations and lines of therapy. The FDA’s anticipated restriction of PD-1 inhibitors to PD-L1-expressing tumors, coupled with the approval of the first-in-class claudin 18.2 inhibitor Vyloy, will further reshape market dynamics in this space.
QUESTIONS ANSWERED
- What are the treatment rates for gastroesophageal cancer in the various settings and lines of therapy?
- What is Vyloy’s impact on the HER2-negative gastroesophageal cancer market?
- What are the leading therapies in the treatment of HER2-positive gastroesophageal cancer?
- What do surveyed oncologists consider the main drivers of and key obstacles to the uptake of select therapies?
PRODUCT DESCRIPTION
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in April 2025.
Key drugs: Cyramza, Enhertu, Herceptin, Keytruda, Lonsurf, Opdivo, Tevimbra, Vyloy, Yervoy
